Hanall Biopharma Co (009420.KS) Osake Kurssi
Hanall Biopharma Co Kurssi
Liikevaihto on kasvanut 3,2 % vuodessa viimeisten 19 vuoden aikana 155,18 Mrd. KRW:een. Osakekohtainen tulos on kasvanut 10,6 % vuodessa viimeisten 17 vuoden aikana. Hanall Biopharma Con nettomarginaali on nyt −3,6 %, laskenut 8,8 %:sta muutama vuosi sitten. Hanall Biopharma Con osinkotuotto on tällä hetkellä noin 0,03 %. Jakosuhde on noin 80 % tuloksesta. Analyytikoiden mediaanitavoitehinta on 42 840,00 KRW, eli yli nykyhintaa 21,4 %. 10 analyytikosta 9 suosittaa ostoa — kokonaiskonsensus on Osta.
Hanall Biopharma Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Hanall Biopharma Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Hanall Biopharma Co -osakkeesta
The business model of Hanall Biopharma Co Ltd is focused on the development and commercialization of innovative pharmaceutical products. As a leading biopharmaceutical company, Hanall Biopharma Co Ltd aims to discover, research, and manufacture high-quality drugs that address unmet medical needs. By leveraging advanced technologies and scientific expertise, the company strives to improve the health and well-being of patients worldwide. With a strong commitment to research and development, Hanall Biopharma Co Ltd consistently seeks new opportunities and collaborations to expand its product portfolio and deliver innovative solutions to the healthcare industry.
Hanall Biopharma Co Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of Hanall Biopharma Co Ltd in the market include companies like Celltrion Inc, Samsung Biologics Co Ltd, and Genexine Inc.
Hanall Biopharma Co Ltd is a leading biopharmaceutical company specializing in the development and commercialization of innovative medicines. Established in [insert year], Hanall Biopharma has a rich history in the biotechnology industry. The company is known for its strong focus on research and development, with a portfolio that includes [highlight key products/services]. Hanall Biopharma has achieved several milestones throughout its history, including [mention significant achievements]. With a commitment to improving patients' lives, Hanall Biopharma continues to drive advancements in the biopharmaceutical sector and is poised for continued success in the future.
Hanall Biopharma Co Ltd has achieved significant milestones in its journey. The company has successfully developed and commercialized various innovative pharmaceutical products, making a remarkable impact on the healthcare industry. Additionally, Hanall Biopharma Co Ltd has demonstrated consistent growth and expansion by establishing strategic partnerships, collaborations, and global presence. With its commitment to research and development, the company has achieved regulatory approvals for several groundbreaking medicines, enhancing treatment options and improving patient outcomes worldwide. Hanall Biopharma Co Ltd continues to strive for excellence, contributing to advancements in healthcare and solidifying its position as a leader in the pharmaceutical sector.
Hanall Biopharma Co Ltd is primarily present in South Korea.
Hanall Biopharma Co Ltd represents a strong commitment to innovation, quality, and patient-centricity. As a leading pharmaceutical company, Hanall Biopharma is dedicated to developing and commercializing innovative medicines that address unmet medical needs. The company's corporate philosophy revolves around scientific excellence, ethical business practices, and sustainable growth. Hanall Biopharma aims to improve patient outcomes through cutting-edge research and development, rigorous quality control, and global partnerships. With a focus on delivering high-value treatments, Hanall Biopharma continues to contribute to the advancement of healthcare and the well-being of patients worldwide.
Analyytikot asettavat tällä hetkellä Hanall Biopharma Co-osakkeelle keskimääräisen tavoitehinnan 44 734,29 KRW (mediaani: 42 840,00 KRW), mikä merkitsee +26,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.
10 analyytikkoa arvioi tällä hetkellä Hanall Biopharma Co-osaketta: 9 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Hanall Biopharma Co-yhtiöltä 172,70 Mrd. KRW liikevaihtoa ja −343,26 KRW osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Hanall Biopharma Co-osake noteerataan hintaan 23,47 EUR (35 300,00 KRW).
Hanall Biopharma Co-osake (009420.KS) on listattuna 1 pörssissä, muun muassa: KOSPI (Seoul) (009420.KS).
Hanall Biopharma is a South Korean biotechnology company focused on manufacturing innovative drugs for the treatment of cancer and rare diseases. The company has a strong presence in the global market for biopharmaceuticals, with over 20 years of experience in the industry. Its business model is centered around research and development, manufacturing, and distribution. Hanall Biopharma invests a significant portion of its revenue in R&D for new drugs and is known for its expertise in developing biologically produced drugs using recombinant DNA technology. The company also specializes in the production of biopharmaceutical products, continuously improving manufacturing processes and technologies to meet international standards and regulations. Its product range includes a variety of biological drugs such as antibodies, vaccines, growth hormones, and enzymes. One of its flagship products is the cancer medication Welix, developed for the therapy of leukemia and lymphomas. Hanall Biopharma distributes its products in multiple countries, including South Korea, the USA, Europe, and China, through collaborations with distributors, healthcare organizations, and government agencies. The company also pursues strategic partnerships with other pharmaceutical companies to expand its development and distribution capabilities and explore new market opportunities. With its vision to improve people's health and well-being through innovative and effective drugs, Hanall Biopharma's continual investments in research and development, advanced technologies, and partnerships position it as a leading player in the biopharmaceutical industry.
odotettu liikevaihto Hanall Biopharma Co on 172,70 Mrd. KRW. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Hanall Biopharma Co on −17,57 Mrd. KRW. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Hanall Biopharma Co:n hinta-voitto-suhde (P/E) on tällä hetkellä −102,84. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Hanall Biopharma Co-osakkeen arvostusta.
Hanall Biopharma Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 10,46. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Hanall Biopharma Co-osakkeen arvostuskennuslukuna.
Hanall Biopharma Co:n Eulpool-laatuscore on 3/10.
Hanall Biopharma Co:n ISIN on KR7009420001. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Hanall Biopharma Co:n ticker on 009420.KS. Tämä pörssinoteeraus käytetään Hanall Biopharma Co-osakkeiden kauppaan pörssissä.
Hanall Biopharma Co osake
Hanall Biopharma Co vertaisryhmä
Hanall Biopharma Co Ticker
Hanall Biopharma Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Hanall Biopharma Co:sta
Meidän osakeanalyysimme Hanall Biopharma Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Hanall Biopharma Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: